Analysts explain ResMed share tumble
06 May, 2002 by Tanya HollisInvestors have lost patience with companies failing to deliver on expectations, analysts said today (Monday, May 6), with ResMed the latest stock hit by their wrath.
Radioactive agreement for Sirtex
03 May, 2002 by Daniella GoldbergSirtex Medical has entered into an agreement with German-based AEA Technology, a supplier of radioactive products, to assist in distributing its SIR-Spheres internationally.
ResMed plummets after earnings warning
03 May, 2002 by Iain ScottSleep disorder specialist ResMed's shares took a beating on the Australian Stock Exchange this morning (May 3), dropping more than 22 per cent when the company suggested that it would not be able to meet its fourth quarter earnings estimate.
Genetic manipulation to free Murray-Darling of carp
02 May, 2002 by Melissa TrudingerCSIRO scientists have hatched an ambitious plan to wipe out carp in the Murray-Darling River, by using genetically manipulated carp that lack the ability to change sex.
BresaGen to build new research facility
02 May, 2002 by Daniella GoldbergAdelaide-based company BresaGen has received $8.9 million from the South Australian government to build a new research facility at the Thebarton Biotechnology Precinct.
Transgenic start-up stalled by grant freeze
02 May, 2002 by Tanya HollisA Melbourne start-up looking at pigs as potential organ donors is among hundreds of Australian businesses to be affected by the suspension of the Federal government's R&D Start program.
Peacock to head Academy of Science
01 May, 2002 by Daniella GoldbergCSIRO Plant Industry chief Dr Jim Peacock has been elected to head the Australian Academy of Science (AAS) after 27 years in the academy.
Analytica achieves its first positive cash flow
01 May, 2002 by Tanya HollisAnalytica has posted its first positive operating cash flow on the back of its takeover by listed medical diagnostics group Psiron last year.
Looking sharp in two hats
30 April, 2002 by Pete YoungScientist-turned-financier Dr Kevin Healey is one of an elite group which has used its life science credentials as a springboard to make a splash as venture capitalists.
Prima technology showing positive results
30 April, 2002 by Tanya HollisPrima Biomed's (ASX: PRR) vaccine platform technology has taken another step towards success by triggering a strong immune response in large animals, the company reported today.
Wilmut disappointed, others happy with cloning progress
30 April, 2002 by Melissa TrudingerRecent media interviews with Dr Ian Wilmut, the scientist responsible for cloning Dolly the sheep, have suggested that all clones are genetically and physically defective.
McGauran promises action on killer jellyfish research
30 April, 2002 by Iain ScottScience Minister Peter McGauran has pledged his support to a call for funding to research the tiny irukandji jellyfish, which has claimed two lives off the Queensland coast this year.
New bio-investor launches IPO
29 April, 2002 by Tanya HollisAustralia's latest biotech share offering opens this week when device and diagnostics investment company Premier Bionics launches its IPO.
ES Cell scores US grant, license deal
29 April, 2002 by Tanya HollisMelbourne's ES Cell International has scored a double coup in the United States with the awarding of a National Institutes of Health infrastructure grant and the signing of a research licensing deal.
BresaGen wins NIH deal
26 April, 2002 by Tanya HollisA second Australian company has won the right to provide embryonic stem cell lines to the National Institutes of Health (NIH) in the United States.
